Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：141頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 9
Therapeutics Development 10
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 10
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 11
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 12
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 15
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 20
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes 21
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
AstraZeneca PLC 23
MedImmune, LLC 24
Isis Pharmaceuticals, Inc. 25
Gilead Sciences, Inc. 26
Daiichi Sankyo Company, Limited 27
Merck & Co., Inc. 28
CardioVascular BioTherapeutics, Inc. 29
Bayer AG 30
AnGes MG, Inc. 31
Pluristem Therapeutics Inc. 32
AngioDesign 33
ViroMed Co., Ltd. 34
Miltenyi Biotec GmbH 35
Multi Gene Vascular Systems Ltd 36
Lonestar Heart, Inc. 37
Biscayne Pharmaceuticals, Inc. 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
cangrelor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
prasugrel hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
anacetrapib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rivaroxaban - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ranolazine ER - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CD133+ Autologous Bone Marrow Stem Cells - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
tetrahydrobiopterin + [folic acid] - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CVBT-141H - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CVBT-141A - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
BQ-123 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ISIS-CRPRx - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
VM-202 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CD 133 Cells - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
XL-652 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
VM-202 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
beperminogene perplasmid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ISIS-APOARx - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ACP-501 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GS-6615 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ACP-01 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PLX Cells for Peripheral Artery Disease - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
GLP-1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MultiGeneGraft - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
BAY-606583 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Growth Hormone-Releasing Hormone Agonists - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Drug For Ischemic Heart Disease - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Anti-CD20 Monoclonal Antibody - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
cangrelor - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 100
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 128
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 129
Featured News & Press Releases 129
Jan 02, 2014: Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist 129
Sep 03, 2013: Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis 129
Jul 12, 2013: Daiichi Sankyo Announces Phase 3 Study Results for the Antiplatelet Agent Prasugrel in Japan 130
Jul 01, 2013: FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor 131
Apr 11, 2013: Amarantus Announces Preclinical Development Timeline For MANF Therapeutic 132
Apr 08, 2013: Resverlogix To Spin-out Innovative Drug R&D subsidiary RVX Therapeutics 133
Apr 01, 2013: Isis Pharma Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides 135
Mar 13, 2013: Isis Pharma Reports Clinical Data Showing Blunting Of Severe Increases In CRP Following Endotoxin Challenge With ISIS-CRP Rx 135
Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto 137
Nov 13, 2012: Bayer Announces Initiation Of COMPASS Phase III Study Of Xarelto For Secondary Prevention Of Myocardial Infarction And Death In Patients With Coronary Or Peripheral Artery Disease 138
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141
List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014 10
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2014 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2014 23
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2014 24
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2014 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 27
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2014 28
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 29
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2014 30
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2014 31
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2014 32
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AngioDesign, H1 2014 33
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2014 34
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2014 35
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2014 36
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2014 37
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Stage and Target, H1 2014 43
Number of Products by Stage and Mechanism of Action, H1 2014 46
Number of Products by Stage and Route of Administration, H1 2014 48
Number of Products by Stage and Molecule Type, H1 2014 51
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2014 100
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2014 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2014 128
List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014 10
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Top 10 Target, H1 2014 41
Number of Products by Stage and Top 10 Target, H1 2014 42
Number of Products by Top 10 Mechanism of Action, H1 2014 44
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 45
Number of Products by Top 10 Route of Administration, H1 2014 47
Number of Products by Stage and Top 10 Route of Administration, H1 2014 48
Number of Products by Top 10 Molecule Type, H1 2014 49
Number of Products by Stage and Top 10 Molecule Type, H1 2014 50
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 9
Therapeutics Development 10
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 10
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 11
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 12
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 15
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 20
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes 21
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
AstraZeneca PLC 23
MedImmune, LLC 24
Isis Pharmaceuticals, Inc. 25
Gilead Sciences, Inc. 26
Daiichi Sankyo Company, Limited 27
Merck & Co., Inc. 28
CardioVascular BioTherapeutics, Inc. 29
Bayer AG 30
AnGes MG, Inc. 31
Pluristem Therapeutics Inc. 32
AngioDesign 33
ViroMed Co., Ltd. 34
Miltenyi Biotec GmbH 35
Multi Gene Vascular Systems Ltd 36
Lonestar Heart, Inc. 37
Biscayne Pharmaceuticals, Inc. 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
cangrelor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
prasugrel hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
anacetrapib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rivaroxaban - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ranolazine ER - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CD133+ Autologous Bone Marrow Stem Cells - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
tetrahydrobiopterin + [folic acid] - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CVBT-141H - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CVBT-141A - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
BQ-123 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ISIS-CRPRx - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
VM-202 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CD 133 Cells - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
XL-652 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
VM-202 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
beperminogene perplasmid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ISIS-APOARx - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ACP-501 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GS-6615 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ACP-01 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PLX Cells for Peripheral Artery Disease - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
GLP-1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MultiGeneGraft - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
BAY-606583 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Growth Hormone-Releasing Hormone Agonists - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Drug For Ischemic Heart Disease - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Anti-CD20 Monoclonal Antibody - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
cangrelor - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 100
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 128
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 129
Featured News & Press Releases 129
Jan 02, 2014: Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist 129
Sep 03, 2013: Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis 129
Jul 12, 2013: Daiichi Sankyo Announces Phase 3 Study Results for the Antiplatelet Agent Prasugrel in Japan 130
Jul 01, 2013: FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor 131
Apr 11, 2013: Amarantus Announces Preclinical Development Timeline For MANF Therapeutic 132
Apr 08, 2013: Resverlogix To Spin-out Innovative Drug R&D subsidiary RVX Therapeutics 133
Apr 01, 2013: Isis Pharma Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides 135
Mar 13, 2013: Isis Pharma Reports Clinical Data Showing Blunting Of Severe Increases In CRP Following Endotoxin Challenge With ISIS-CRP Rx 135
Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto 137
Nov 13, 2012: Bayer Announces Initiation Of COMPASS Phase III Study Of Xarelto For Secondary Prevention Of Myocardial Infarction And Death In Patients With Coronary Or Peripheral Artery Disease 138
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141
List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014 10
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2014 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2014 23
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2014 24
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2014 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 27
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2014 28
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 29
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2014 30
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2014 31
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2014 32
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AngioDesign, H1 2014 33
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2014 34
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2014 35
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2014 36
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2014 37
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Stage and Target, H1 2014 43
Number of Products by Stage and Mechanism of Action, H1 2014 46
Number of Products by Stage and Route of Administration, H1 2014 48
Number of Products by Stage and Molecule Type, H1 2014 51
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2014 100
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2014 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2014 128
List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2014 10
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Top 10 Target, H1 2014 41
Number of Products by Stage and Top 10 Target, H1 2014 42
Number of Products by Top 10 Mechanism of Action, H1 2014 44
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 45
Number of Products by Top 10 Route of Administration, H1 2014 47
Number of Products by Stage and Top 10 Route of Administration, H1 2014 48
Number of Products by Top 10 Molecule Type, H1 2014 49
Number of Products by Stage and Top 10 Molecule Type, H1 2014 50
